GlaxoSmithKline takes legal action to block new controls on its smoking cessation drugBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7396.952/a (Published 03 May 2003) Cite this as: BMJ 2003;326:952
- Melissa Sweet
Leading researchers have attacked the pharmaceutical giant GlaxoSmithKline for trying to block proposed new controls on the smoking cessation treatment bupropion (Zyban) in Australia.
The plan, which requires that patients have a second GP consultation to get a full prescription, was developed in response to concerns about costly waste of the treatment.
But the company has taken legal action, arguing that the Pharmaceutical Benefits Advisory Committee does not have the authority to make changes once drugs have been listed for subsidy. The company also claims that the committee's procedures denied it natural justice.
Prominent researchers, including Professor Simon …
Log in using your username and password
Log in through your institution
Sign up for a free trial